» Articles » PMID: 12011818

Tissue Distribution of Imipenem in Critically Ill Patients

Overview
Publisher Wiley
Specialty Pharmacology
Date 2002 May 16
PMID 12011818
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Methods: Imipenem is a broad-spectrum antibiotic used mainly for serious infections in critically ill patients. Because the infection originates mostly from a certain tissue, we assessed tissue concentrations of imipenem using microdialysis in patients in intensive care with serious infections compared with healthy volunteers. Most patients were >60 years old and had renal failure; most patients also had impaired liver, heart, or lung function.

Results: Muscle and subcutaneous tissue concentrations in patients (maximum of 2.3 +/- 1.5 microg/mL for both muscle and subcutaneous tissue) were significantly lower than those in healthy subjects (maximum of 12.8 +/- 1.6 and 10.7 +/- 1.0 microg/mL for muscle and subcutaneous tissue). The tissue distribution rate constants for muscle and subcutaneous tissue were also significantly lower in patients (1.95 +/- 0.6 and 1.1 +/- 0.2 h(-l), respectively) than in healthy subjects (5.2 +/- 1.0 and 6.6 +/- 1.7 h(-1), respectively), meaning that tissue distribution in patients was reduced and retarded. Values for area under the plasma concentration-time curve did not significantly differ between patients and healthy subjects (37.4 +/- 5.9 microg. h/mL and 46.0 +/- 4.4 microg. h/mL, respectively,) although the elimination of imipenem in patients was prolonged (clearance, 6.3 +/- 0.8 L/h and 13.2 +/- 1.4 L/h in patients and healthy subjects, respectively).

Conclusions: Our data suggest that the amount and velocity of imipenem tissue distribution in seriously ill patients is reduced compared with those values in healthy volunteers. Dose adjustments that are exclusively based on plasma concentration data may therefore be misleading and may result in potential underdosing.

Citing Articles

Amphotericin B tissue penetration and pharmacokinetics in healthy and -infected rats: insights from microdialysis and population modeling.

Santos V, Pereira L, de Araujo J, Borges M, Brandao C, Santos L Front Pharmacol. 2025; 15:1515462.

PMID: 39867661 PMC: 11757102. DOI: 10.3389/fphar.2024.1515462.


Artificial Intelligence to Close the Gap between Pharmacokinetic/Pharmacodynamic Targets and Clinical Outcomes in Critically Ill Patients: A Narrative Review on Beta Lactams.

Goncalves Pereira J, Fernandes J, Mendes T, Gonzalez F, Fernandes S Antibiotics (Basel). 2024; 13(9).

PMID: 39335027 PMC: 11428226. DOI: 10.3390/antibiotics13090853.


Understanding antimicrobial pharmacokinetics in critically ill patients to optimize antimicrobial therapy: A narrative review.

Roger C J Intensive Med. 2024; 4(3):287-298.

PMID: 39035618 PMC: 11258509. DOI: 10.1016/j.jointm.2023.12.007.


Quantitative Determination of Unbound Piperacillin and Imipenem in Biological Material from Critically Ill Using Thin-Film Microextraction-Liquid Chromatography-Mass Spectrometry.

Wlodarski R, Zuchowska K, Filipiak W Molecules. 2022; 27(3).

PMID: 35164191 PMC: 8839241. DOI: 10.3390/molecules27030926.


Predicting Antimicrobial Activity at the Target Site: Pharmacokinetic/Pharmacodynamic Indices versus Time-Kill Approaches.

van Os W, Zeitlinger M Antibiotics (Basel). 2021; 10(12).

PMID: 34943697 PMC: 8698708. DOI: 10.3390/antibiotics10121485.